Microba Life Sciences (ASX: MAP) — Company Overview, News & Financial Data
Microba Life Sciences is a precision microbiome company developing therapeutics and diagnostic tools for health.
Microba Life Sciences
Microba Life Sciences is a precision microbiome company focused on human gut health testing and therapeutic discovery. Founded in Australia, the company utilizes metagenomic sequencing, custom bioinformatics pipelines, and a human gut microbiome database to measure microbial communities. Commercial operations deliver clinical-grade gut health testing services and personalized dietary recommendations to healthcare practitioners and patients across Australia, the United Kingdom, and global distribution markets. Furthermore, the company leverages data-driven insights from its high-resolution biological database to discover novel diagnostic targets and live biotherapeutic leads for inflammatory bowel disease, autoimmune disorders, and gastrointestinal conditions.
Snapshot
Operations
Products and/or services of Microba Life Sciences
- Clinical Microbiome Testing: Comprehensive gut health mapping using metagenomic next-generation sequencing, combining mNGS, PCR, and ELISA techniques to analyze microbial species, 40 functional biomarkers, and gastrointestinal pathogens, delivering evidence-graded reports for healthcare practitioners across domestic and international healthcare markets.
- GI Diagnostic Solutions: Specialized clinical testing tools designed for healthcare professionals to evaluate complex gastrointestinal symptoms, featuring integrated patient assessments, gut physiology panels, targeted pathogen screening, and digital reports accessible through a centralized web portal platform.
- Microbiome Therapeutics Development: Research and drug discovery operations utilizing a proprietary human gut database and bioinformatics pipelines to discover novel biological targets and live biotherapeutic leads focused on treating inflammatory bowel disease, oncology indications, and autoimmune disorders.
- Global Licensing and Partnerships: Strategic commercial distribution agreements with diagnostic companies and clinical healthcare networks in North America, Europe, and Asia-Pacific, enabling white-label and co-branded deployment of microbiome diagnostic technology across global clinical laboratory partners.
- Healthcare Practitioner Platform: Digital portal tools and clinical support services offering interactive test interpretation, live report sharing, case consultations with microbiome specialists, and over 50 evidence-based clinical guides and educational resources for practicing health professionals.
- Pathology Laboratory Operations: Centralized laboratory processing facilities operating under ISO 15189 human pathology accreditation standards in Australia, utilizing automated sample extraction, high-throughput DNA sequencing platforms, and custom bioinformatics pipelines to process practitioner and patient samples globally.
Microba Life Sciences executive team
- Gene TysonCo-Founder & Non-Executive Director
- James HeathCFO & Company Secretary
- Luke ReidChief Executive Officer (Leave of Absence)
- Geoffrey C. CockerillInterim Chief Executive Officer
- Philip HugenholtzCo-Founder & Chair of Scientific Advisory Board
- David WoodChief Technology Officer
- Lutz KrauseChief Scientific Officer
- Nicola AngelHead of Laboratory Operations & Laboratory Director
- Keith ByrneHead of Test Operations
- Eric DaviesChief Revenue Officer
Latest news about Microba Life Sciences
Recent announcements
What Microba Life Sciences (MAP) has told the market, newest first.
- Notification of cessation of securities - MAP
- Microba launches GI Navigator in Australia and the UK
- Change in substantial holding
- Change in substantial holding
- Cleansing Notice
- Letter to SPP Eligible Shareholders
- Disclosure Document - ProspectusPrice sensitive
- Application for quotation of securities - MAP
Key financials
Reported results for Microba Life Sciences, in AUD.
- Market cap
- 25.6M
- Revenue (TTM)
- 14.8M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- -140.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 14.8M | -20.3M | -20.7M | |
| 15.7M | -24.6M | -14.9M | |
| 12.1M | -26.8M | -19.9M | |
| 5.4M | -20.2M | -12.7M |